Li Wenhua, Yu Yaren, He Haiyan, Chen Jing, Zhang Debin
Department of Cardiology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
Biomed Rep. 2015 Jul;3(4):509-512. doi: 10.3892/br.2015.449. Epub 2015 Apr 16.
With the improvement of the skill level of coronary intervention, contrast agents are used more widely. As a result, contrast-induced acute kidney injury (CI-AKI) is currently the third leading cause of hospital-acquired AKI. Traditionally, AKI is defined by measuring an increase of the serum creatinine concentration (Scr). CI-AKI indicates impairment in renal function, which is diagnosed as an elevation in the SCr levels following intravascular injection of the contrast media. However, Scr is an insensitive indicator for detecting CI-AKI. The present study was designed to investigate whether human urinary kidney injury molecule-1 (KIM-1) is an early marker to predict CI-AKI in patients with diabetes mellitus undergoing percutaneous coronary intervention (PCI). The present study includes the general clinical data of 145 patients with diabetes mellitus who underwent PCI between March 1, 2013 and December 31, 2013. A non-ionic, low osmolarity contrast agent was used during the present study. The Scr levels and estimated glomerular filtration rate were measured prior to and within 24 and 48 h after the injection of contrast agents. Urinary samples were collected prior to and within 2, 6, 12, 24 and 48 h after the coronary interventional procedure. Simultaneously, the urinary KIM-1 values were measured using an ELISA kit. CI-AKI was diagnosed as an increase of ≥0.5 mg/dl or ≥25% in Scr concentration over baseline, 24-48 h after the procedure. In total, 19 of 145 (13.1%) patients exhibited CI-AKI. There was a significant difference (P<0.05) between the urinary KIM-1 levels measured 2, 6, 12, 24 and 48 h after the procedure and those prior to the procedure in the CI-AKI group. There was no significant difference between the Scr values measured 24 h after the procedure and those prior to the procedure. Evidently, using KIM-1 values to predict CI-AKI was <24 h earlier compared to using Scr values. The area under the receiver operating characteristic curve of KIM-1 24 h after the procedure was 0.856 and the 95% confidence interval of the corresponding area was 0.782-0.929. When the pivotal point of CI-AKI diagnosis was 6,327.755 pg/ml, the specificity was 85.7% and the sensitivity was 73.7%. Univariate analysis showed that the Scr concentration was positively correlated with the urinary KIM-1 level during the time prior to the procedure and 24 and 48 h after the procedure. In conclusion, the urinary KIM-1 may be a potential indicator for the early diagnosis of CI-AKI.
随着冠状动脉介入技术水平的提高,造影剂的使用越来越广泛。因此,造影剂诱导的急性肾损伤(CI-AKI)目前是医院获得性急性肾损伤的第三大主要原因。传统上,急性肾损伤是通过测量血清肌酐浓度(Scr)的升高来定义的。CI-AKI表明肾功能受损,其被诊断为血管内注射造影剂后Scr水平升高。然而,Scr是检测CI-AKI的不敏感指标。本研究旨在调查人尿肾损伤分子-1(KIM-1)是否是预测接受经皮冠状动脉介入治疗(PCI)的糖尿病患者发生CI-AKI的早期标志物。本研究纳入了2013年3月1日至2013年12月31日期间接受PCI的145例糖尿病患者的一般临床资料。本研究期间使用了非离子型、低渗造影剂。在注射造影剂之前以及注射后24小时和48小时内测量Scr水平和估计肾小球滤过率。在冠状动脉介入手术后之前以及术后2、6、12、24和48小时内收集尿液样本。同时,使用酶联免疫吸附测定试剂盒测量尿KIM-1值。CI-AKI被诊断为术后24 - 48小时Scr浓度较基线水平升高≥0.5 mg/dl或≥25%。总共145例患者中有19例(13.1%)发生CI-AKI。在CI-AKI组中,术后2、6、12、24和48小时测量的尿KIM-1水平与术前相比存在显著差异(P<0.05)。术后24小时测量的Scr值与术前相比无显著差异。显然,与使用Scr值相比,使用KIM-1值预测CI-AKI要早于24小时。术后24小时KIM-1的受试者工作特征曲线下面积为0.856,相应面积的95%置信区间为0.782 - 0.929。当CI-AKI诊断的临界点为6327.755 pg/ml时,特异性为85.7%,敏感性为73.7%。单因素分析表明,术前以及术后24小时和48小时期间Scr浓度与尿KIM-1水平呈正相关。总之,尿KIM-1可能是CI-AKI早期诊断的潜在指标。